All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings

Background Recent World Health Organization guidance on drug-resistant tuberculosis treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of the injectable agent, particularly in the context of regimens using new and repurposed drugs. We compared the effectiveness of an injectable-containing regimen to that of an all-oral regimen among patients with drug-resistant tuberculosis who received bedaquiline and/or delamanid as part of their multidrug regimen. Methods Patients with a positive baseline culture were included. 6-month culture conversion was defined as two consecutive negative cultures collected >15 days apart. We derived predicted probabilities of culture conversion and relative risk using marginal standardisation methods. Results Culture conversion was observed in 83.8% (526 out of 628) of patients receiving an all-oral regimen and 85.5% (425 out of 497) of those receiving an injectable-containing regimen. The adjusted relative risk comparing injectable-containing regimens to all-oral regimens was 0.96 (95% CI 0.88-1.04). We found very weak evidence of effect modification by HIV status: among patients living with HIV, there was a small increase in the frequency of conversion among those receiving an injectable-containing regimen, relative to an all-oral regimen, which was not apparent in WV-negative patients. Conclusions Among individuals receiving bedaquiline and/or delamanid as part of a multidnig regimen for drug-resistant tuberculosis, there was no significant difference between those who received an injectable and those who did not regarding culture conversion within 6 months. The potential contribution of injectable agents in the treatment of drug-resistant tuberculosis among those who were HIV positive requires further study.

Automated summary

This study compared the effectiveness of an injectable regimen to an all-oral regimen in patients with drug-resistant tuberculosis who received bedaquiline and/or delamanid as part of their treatment. The results showed no significant difference in culture conversion within 6 months between those who received an injectable and those who did not, except for a small increase in conversion frequency among HIV-positive patients receiving an injectable regimen. Further research is needed on the potential contribution of injectable agents in the treatment of drug-resistant tuberculosis among HIV-positive patients.